Over 7 years, the US health care system spent more than $3 billion on DMD treatments eteplirsen, golodirsen, and casimersen, despite a lack of confirmatory trial data.
— cost the US health care system more than $3 billion between 2016 and 2022, despite a lack of confirmatory efficacy data, a new analysis showed.
Overall sales for the drugs increased from $7 million in 2016 to $879 million in 2022, while Medicaid and Medicare spending rose from $25 million in 2017 to $327 million in 2022. The findings point to the importance of follow up on drugs that are approved with preliminary evidence, Rome said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
More Kids, Teens May Be Taking Multiple Psychiatric MedsA study of mental health care in Maryland finds an increasing number of children and teens covered by Medicaid are taking multiple psychiatric meds.
Read more »
Teens use HIV prevention meds way more if they get these simple interventionsNicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She holds a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida.
Read more »
SF program disposes 3 Muni buses of medsFrom 2017 to 2022, the Safe Medicine Disposal Program successfully diverted hundreds of thousands of pounds of unused medications in an effort to prevent harmful medications from coming into contact with people or polluting the environment
Read more »
Statin Meds & Cholesterol: What You Need to KnowStatins have become the miracle medicine of modern heart care, lowering cholesterol levels and and guarding against heart attacks in millions of Americans.
Read more »
Sun Plus Certain Foods, Meds Can Bring on 'Margarita Rashes'Slicing some fresh limes for that margarita savored in the sun could be a bad combo for some people's skin, dermatologists warn.
Read more »
New Non-Opioid Pain Meds Hold Promise, But Face Clinical Development And Insurer ChallengesI'm an independent healthcare analyst with more than 25 years of experience analyzing, publishing and presenting/educating on healthcare policy and pharmaceuticals. I have 114 publications in peer-reviewed journals, in addition to more than 450 articles in periodicals and newspapers. I have also presented my work at numerous conferences.
Read more »